Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
7
Bullish
3
Bearish
30
Neutral
8
Bullish
8
Bearish
26
Neutral
1
Bullish
5
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA.
The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix.
Syschem has materially increased production volumes year-on-year (1,269 MT to 1,780 MT) and reported quarterly ramp to 820 MT in Q3 FY25-26, indicating improving capacity utilization ahead of announced expansion; management explicitly states a strategic focus on increasing year-on-year production to capture rising API demand and export opportunities.
Exports are accelerating: export sales increased to ₹107.62 crore in 9M FY25-26 versus ₹90.89 crore in FY24-25, with Q3 exports doubling year-on-year, indicating successful market traction overseas and the potential to diversify revenue as domestic volumes also expand across 12 Indian states and multiple international markets.
The board emphasizes reliable supply, world-class quality and continuous innovation as core strategic pillars; with an experienced promoter-led management team and a growing client list of domestic formulators, Syschem positions itself as a mid-sized, quality-focused API supplier pursuing scale and regulatory alignment to win larger institutional customers.
Pharmaceuticals & Biotechnology
Pharmaceuticals
202 Cr
Moderate Risk
29.5
32.0
—
2.1
62.00
35.33
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q3 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Syschem (India) Ltd (SYSCHEM) is currently trading at 46.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA. The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix. Syschem has materially increased production volumes year-on-year (1,269 MT to 1,780 MT) and reported quarterly ramp to 820 MT in Q3 FY25-26, indicating improving capacity utilization ahead of announced expansion; management explicitly states a strategic focus on increasing year-on-year production to capture rising API demand and export opportunities. Exports are accelerating: export sales increased to ₹107.62 crore in 9M FY25-26 versus ₹90.89 crore in FY24-25, with Q3 exports doubling year-on-year, indicating successful market traction overseas and the potential to diversify revenue as domestic volumes also expand across 12 Indian states and multiple international markets. The board emphasizes reliable supply, world-class quality and continuous innovation as core strategic pillars; with an experienced promoter-led management team and a growing client list of domestic formulators, Syschem positions itself as a mid-sized, quality-focused API supplier pursuing scale and regulatory alignment to win larger institutional customers.
Over the past 52 weeks, Syschem (India) Ltd has traded between a low of ₹35.33 and a high of ₹62.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Syschem (India) Ltd has a market capitalization of approximately 201.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Syschem (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 201.68 Cr, Syschem (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Syschem (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Syschem (India) Ltd is 29.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Discovery themes featuring this stock
Warrant Conversion
Board approved allotment of 5,500,000 equity shares on conversion of 5,500,000 warrants at an issue price of Rs.49 each (Rs.10 FV, Rs.39 premium) on 13-Mar-2026; Rs.202,125,000 received (at Rs.36.75 per warrant) and paid-up capital increased to Rs.49,013,0000.
Preferential Allotment
Board (13‑Mar‑2026) approved conversion/allotment of 5,500,000 warrants into 5,500,000 equity shares at Rs.49 each (Rs.39 premium) on a preferential basis; company received Rs.20,21,25,000 (75% consideration); paid‑up capital now Rs.49,013,000; new shares rank pari‑passu.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
10.89 | 216 Cr | -0.60 | 0.30 | 0.00 | -18.17 | -14.48 | -19.57 | |
171.95 | 207 Cr | -7.58 | 37.99 | 0.00 | -417.29 | -15.11 | -17.94 | |
27.02 | 207 Cr | 19.87 | 1.40 | 0.00 | 10.60 | 10.22 | 4.24 | |
46.35 | 202 Cr | 29.52 | 2.13 | 0.00 | 4.78 | 5.68 | 4.50 | |
163.75 | 201 Cr | 25.74 | 4.48 | 0.30 | 16.63 | 19.07 | 11.42 | |
155.00 | 190 Cr | 64.58 | 2.34 | 0.00 | 4.68 | 6.44 | 3.59 | |
51.49 | 190 Cr | -10.51 | 0.00 | 0.00 | 46.67 | -53.26 | -15.44 | |
| Median: 7 Co. | 51.49 | 202 Cr | 19.87 | 2.13 | 0.00 | 4.78 | 5.68 | 3.59 |
